<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852588</url>
  </required_header>
  <id_info>
    <org_study_id>ENDO-SABR</org_study_id>
    <secondary_id>ReDA #11162</secondary_id>
    <nct_id>NCT04852588</nct_id>
  </id_info>
  <brief_title>Chest Lymph Node Sampling in Patients With Advanced Lung Cancer to be Treated With Curative-intent Radiation Treatment</brief_title>
  <official_title>Endoscopic Nodal Staging in Oligometastatic Non-small Cell Lung Cancer (NSCLC) Being Treated With Stereotactic Ablative Radiotherapy (ENDO-SABR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academic Medical Organization of Southwestern Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the role of sampling suspicious chest lymph nodes with a&#xD;
      procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration&#xD;
      (EBUS-TFNA) or transesophageal ultrasound-guided fine needle aspiration (EUS-FNA) in patients&#xD;
      planned to receive radical dose radiation.&#xD;
&#xD;
      This study will use Stereotactic Ablative Radiotherapy (SABR) for treatment methods. SABR is&#xD;
      a newer radiation treatment that delivers high-dose, precise radiation to small tumors and&#xD;
      can be delivered more accurately than with older radiation treatment methods. It is&#xD;
      considered a standard treatment for small lung cancers, and select cancers that have spread&#xD;
      to the brain.&#xD;
&#xD;
      The purpose of this study is to compare if the lymph node sampling procedure is valuable for&#xD;
      determining the extend of nodal disease in metastatic Non-Small Cell Lung Cancer (NSCLC)&#xD;
      compared to imaging alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 9, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes to treatment intent and/or plan</measure>
    <time_frame>2 years</time_frame>
    <description>Number of patients whose treatment is changed from stereotactic ablative radiotherapy (SABR) to conventional dose radiation, change in mediastinal radiation field, change from curative intent to palliative intent treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the proportion of patients with occult mediastinal metastasis</measure>
    <time_frame>2 years</time_frame>
    <description>Pre-staging treatment planning anticipated lymph nodes to be treated compared to post staging lymph nodes to be treated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the sensitivity and specificity of radiologic staging of hilar/mediastinal lymph nodes</measure>
    <time_frame>2 years</time_frame>
    <description>Nodal staging on imaging alone versus nodal staging after sampling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify the total number of lymph nodes sampled per procedure</measure>
    <time_frame>2 years</time_frame>
    <description>Record the total number of lymph nodes sampled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify the nodal stations sampled</measure>
    <time_frame>2 years</time_frame>
    <description>Record the nodal stations that were sampled</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the proportion of patients with complications of endoscopic procedure</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants with complications versus number without</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">29</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Small pieces of suspicious chest lymph nodes will be removed with a procedure called endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine needle aspiration (EUS-FNA).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA)</intervention_name>
    <description>Chest lymph node sampling procedure by EBUS</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transesophageal ultrasound-guided fine needle aspiration (EUS-FNA)</intervention_name>
    <description>Chest lymph node sampling procedure by EUS</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with oligometastatic non-small cell lung cancer (NSCLC), including a primary&#xD;
             lung tumour (Â± hilar/mediastinal adenopathy) with up to 5 synchronous metastases&#xD;
&#xD;
          -  Radical treatment intent to all sites is recommended at multi-disciplinary tumour&#xD;
             board or by discussion by medical oncologist and radiation oncologist and/or surgeon.&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Good performance status (Eastern Cooperative Oncology Group [ECOG 0-1) with&#xD;
             life-expectancy of at least 6 months as determined by enrolling physician&#xD;
&#xD;
          -  Patient has undergone staging investigations less than 3 months prior to registration.&#xD;
&#xD;
               1. Positron Emission Tomography (PET) / Computed Tomography (CT) and Magnetic&#xD;
                  Resonance Imaging (MRI) brain (CT brain with contrast if contraindication to MRI)&#xD;
                  OR&#xD;
&#xD;
               2. CT chest/abdomen, radionucleotide bone scan and MRI of brain (CT brain with&#xD;
                  contrast if contraindication to MRI)&#xD;
&#xD;
          -  Pathologic confirmation of NSCLC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to Endobronchial Ultrasound (EBUS) / Endoscopic Ultrasound (EUS)&#xD;
&#xD;
          -  Unable to provide consent for EBUS/EUS&#xD;
&#xD;
          -  Contraindication to chest radiotherapy&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inderdeep Dhaliwal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre, Lawson Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Inderdeep Dhaliwal, MD</last_name>
    <phone>519-685-8500</phone>
    <phone_ext>76596</phone_ext>
    <email>Inderdeep.Dhaliwal@lhsc.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Palma, MD</last_name>
    <phone>519-685-8650</phone>
    <email>David.Palma@lhsc.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>London Health Sciences Centre - London Regional Cancer Program</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inderdeep Dhaliwal, MD</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>76596</phone_ext>
      <email>Inderdeep.Dhaliwal@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>David Palma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Mitchell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mehdi Qiabi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Louie, MD</last_name>
      <phone>416-480-4951</phone>
      <email>Alexander.Louie@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Christine MacDonald, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harvey Wong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oligometastatic Non-Small Cell Lung Cancer</keyword>
  <keyword>Stereotactic Ablative Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

